IBRANCE – New treatment for breast cancer

15/10/2016 4684 Views
IBRANCE – New treatment for breast cancer

The European Medicines Agency (EMA) has recommended for marketing authorisation in the EU a new treatment option for women with advanced or metastatic disease. The drug, called Ibrance, is to be used to treat cancer that is hormone receptor positive and human epidermal growth factor receptor 2 negative. The EMA opinion will be sent to the European Commission, which retains the final say in granting EU-wide marketing authorisation for any medicines.

Ibrance works by blocking the activity of proteins and inhibiting the division of cancer cells, thus helping to stop the growth of the cancerous tumour. The drug is to be used in combination with an aromatase inhibitor.

Tests of Ibrance have shown that patients receiving both an aromatase inhibitor and Ibrance lived on average 24.8 months without their disease getting worse, compared to 14.5 months for patients who only received an aromatase inhibitor. The tests identified several side effects of using Ibrance, such as infections, fatigue, nausea, vomiting, inflammation of the lining of the mouth, diarrhoea, hair loss, as well as myelosuppression, a condition in which the patient’s bone marrow produces fewer blood cells than normal.

Breast cancer is the most common cancer in women worldwide. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 deaths from the disease. Hormone receptor positive breast cancer accounts for 65{cabf78295431282ca1bec49ffbe2c87b89a1285ae102b2d0687184fc21af24ba} of tumours in women aged 35 to 65 years and 82{cabf78295431282ca1bec49ffbe2c87b89a1285ae102b2d0687184fc21af24ba} of tumours in women older than 65 years.

Find out more here

Related articles